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Abstract 
Sex.  Most individuals have had or will have sexual intercourse or sexual activity 
at some point in their lives.  When individuals have sexual activity, regardless of their 
age, gender, race, ethnicity, marital status or sexual orientation, there is a level of risk 
with contracting a sexually transmitted infection (STI).  STIs are common among the 
United States population, as more than half of all people in the United States will have 
an STI at some point in their lifetime (Koutsky, 1997).  One of the most common of 
these STIs is caused by human papillomavirus (HPV).  Of the more than 100 types of 
HPV that can affect various parts of the body, 30 are regarded as transmitted primarily 
through sexual activity.  As stated by many organizations including the American Social 
Health Association (ASHA), genital HPV is common.  It is contracted by approximately 
80% of sexually active women and men at some point during their lifetime (Koutsky, 
1997).  Further, more than half of all STI cases were among adolescents and young 
adults between the ages of 15 and 24 during the year 2000, with 88% of those new STI 
cases resulting from HPV, trichomoniasis and Chlamydia (Weinstock, 2004).  Specific to 
HPV overall, there are approximately 6.2 million new cases each year in the United 
States (Steinbrook, 2006).  
Genital HPV is most often a minor, asymptomatic condition that is typically held 
under control by an individual’s immune system.  Still, according to many sources 
including the International Agency for Research on Cancer (IARC), certain HPV types 
can serve as co-factors for cancers of the cervix, vagina, vulva, and anus in women, 
and of the penis and anus in men (IARC, 1995).  Of these conditions, cervical cancer is 
the most common and is more commonly associated with high risk types of HPV (CDC, 
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2009).  HPV information and awareness efforts are often targeted more toward the 
female population as cervical cancer can only occur in females.  Additionally, HPV 
tends to only cause benign symptoms in men such as genital warts or bumps, whereas 
it can cause cervical cancer precursors (cervical dysplasia) in women.  Although it is 
important for women to become educated about HPV, males are also in need of 
information on the virus.   The intent of this paper is to identify the prevalence, 
characteristics, and issues surrounding HPV and discuss how topics such as 
awareness, symptoms, testing, treatment, risk reduction, vaccines, and psychosocial 
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Genital HPV: The Problem 
The World Health Organization (WHO) defines health as, “a state of complete 
physical, mental and social well-being and not merely the absence of disease or 
infirmity” (Turnock, 2007).   Individuals can be in good health and still have viruses such 
as HPV.  As human beings, we are exposed to viruses each and every day, and, as our 
bodies are perfect “hosts” for viruses, we often contract them with or without knowledge.  
HPV is an example of a virus that can cause infection, but not disease.  More simply 
put, it is a virus that individuals can unknowingly have for many years.  An estimated 5.5 
million individuals contract HPV each year in the United States, and an estimated 20 
million individuals currently have the virus (Cates, 1999).  “Currently” is the key phrase 
here, as many individuals’ immune systems are able to clear the virus to undetectable 
levels.  A study conducted by Ho and reported in 1998, showed that in 91% of women 
with new HPV infections, HPV became undetectable within just two years (Ho, 1998).  
However, reactivation at any point for females or males is a possibility.  A key element 
about HPV is that it is actually a family of viruses with different geno types that affect 
different areas of the body.  These different viral types fall into classifications of low risk 
and high risk, and can affect males and females symptomatically and asymptomatically 
in separate ways.  While this paper will go into more detail with cervical cancer, genital 
HPV can also serve as a cofactor to other cancers as documented by Parkin.  HPV is 
estimated to be responsible for approximately 90% of anal cancers and about 40% of 
vulvar, vaginal, and penile cancers (Parkin, 2006).   
Genital warts are referred to as low risk types and rarely cause complications of 
any kind.  These low risk types can be found in either gender and can appear not only 
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as warts but also as simple growths or bumps, raised or flat, single or multiple, that 
cause little to no pain or discomfort.  These symptoms can appear anywhere in the 
genital region below the waist and above the thighs including the penis, scrotum, 
vagina, vulva, anus, groin and buttocks.  These symptoms may never appear or show 
for weeks, months or years after contracting the virus.  They may disappear on their 
own, and may be a single occurrence or potentially recur again. Hence, it is virtually 
impossible for one to know when and from whom they contracted the virus.   
There are also high risk types that do not affect men but affect women by 
causing cell changes to the cervix, referred to as cervical dysplasia.  These abnormal 
cell changes can be found by healthcare providers via a Pap test (sometimes referred to 
as Pap smear) where a sample of cells is taken from the woman’s cervix.  This is a 
standard test for detecting precancerous cells or tumors.  Although not a guarantee, 
these high risk types can contribute to the development of cervical cancer.  HPV is the 
cause of almost all cervical cancer (Walboomers, 1999).  Cervical cancer is not rare and 
is the 11th most common cancer among women in the United States (Steinbrook, 2006).  
As of 2006, approximately 9,710 cases were documented and approximately 3,700 
women died (Steinbrook, 2006).  Per the Centers for Disease Control and Prevention, 
an estimated 10,800 cases of cervical cancer occur each year in the United States 
(CDC, 2009).  In terms of race and ethnicity, more African American and Hispanic 
women develop cervical cancer and are diagnosed at later stages than women of other 
races and ethnicities.  Approximately 14 Hispanic women, 8 white women, 13 African 
American women, and 8 Asian/Pacific Islander women were diagnosed with cervical 
cancer per 100,000 women between 1998 and 2003 (Watson, 2008).   The median age 
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of diagnosis for cervical cancer was 47 years (Watson, 2008).  Additionally as reported 
by Benard, roughly 10 out of every 100,000 women who live in poorer counties (defined 
as counties where more than 10% of residents have an income below the federal 
poverty level) are diagnosed with cervical cancer each year.  The rate climbs to 13 
women per 100,000 in counties in which less than 20% of residents are below poverty 
level, and peaks at about 19 per women 100,000 in poorer counties (Benard, 2008).  
As of 2005, roughly 25 states had cervical cancer rates between 7.9 and 12.8 per 
1,000 individuals according to the National Cancer Institute or NCI (NCI, 2005).  There 
were 12 states and the District of Columbia with incidence rates between 8.7 and 12.8 
as displayed in Figure A from the National Cancer Institute.  Additionally, there were 12 
states with rates between 7.9 and 8.6 as indicated by the incidence rates in Figure A 
from NCI.  All other states, shown in Figure A in purple, had rates below 7.9.  These 
overall rates should be considered too high in light of the United States having one of 
the highest amounts of yearly spending on healthcare (WHO, 2008). 
 
Figure A: Cervical Cancer Incidence in United States 
Cervical Cancer Incidence Rates 2005 
Surveillance, Epidemiology, and End Results (SEER) 
Program, National Cancer Institute (NCI) 1975–1991 = 




8.7 to 12.8 
Incidence Rate 
Alaska, Arkansas, Delaware, District of 
Columbia, Florida, Kentucky, Louisiana, 
Nevada, New Mexico, New York, 
Tennessee, Texas, and West Virginia 
7.9 to 8.6 
Incidence Rate 
Alabama, California, Georgia, Illinois, 
Missouri, New Jersey, North Carolina, 
Ohio, Oklahoma, Pennsylvania, Rhode 
Island, and South Dakota 
Less than 7.9 
Incidence Rate 
All remaining states 
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Genital HPV: Characteristics and Issues 
HPV infections are common among men of all ages (Giuliano, 2008).   Males 
who are sexually active or will be at some point in their lives need to be empowered with 
information on HPV.  For their own benefit as well as the benefit of their partner, gaining 
knowledge of HPV and its potential effects on the body is worthwhile for men. Strategies 
for increasing men’s access to accurate, non-alarmist information is warranted and 
programs offering such information should be implemented nationally.  Programs, 
outreach efforts, and initiatives with the goal of educating the public on HPV should 
consider the importance of offering gender-specific information as part of a 
comprehensive approach.  Based on my 11 years of experience at addressing sexually 
transmitted infections, I will discuss the HPV topics below: 
 Who gets HPV? 
 Transmission 
 Signs and symptoms 
 Risk and risk reduction 
 Testing 
 Treatment options 




Who gets HPV? 
Just as any female who has had sexual activity could contract HPV, any male 
who has been sexually active could contract the virus as well.  It is not a matter of being 
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good or bad, clean or dirty, or deserving of contracting it; the simple fact is sexual 
activity engenders a risk for contracting the virus.  The CDC estimates that most 
sexually active people in the United States will contract HPV at some point during their 
lifetime (CDC, 2009).  Most experts agree that the majority of sexually active people will 
be exposed to the virus at some point in their lives and potentially contract it 
unknowingly.  Individuals with HPV span across all demographics and it is estimated 
that approximately 80% of sexually active women and men contract HPV at some point 
during their lifetime (Koutsky, 1997).  One challenge is that most individuals simply do 
not know they have the virus and can pass it to a partner unknowingly, which takes us 




 Genital HPV can be spread by direct, skin-to-skin contact during vaginal or anal 
sex, as well as genital-to-genital contact.  It is important to note that an individual may 
not have intercourse, but still contract the virus through intimate genital contact where 
one person’s skin touches another person’s skin.  Oral sex, where an individual’s mouth 
touches the genital region of another person, has been correlated with HPV in the 
mouth and oropharyngeal cancer (D’Souza, 2007).  However, little is confirmed about 
oral HPV infection (Syrjänen, 2007).  Still, while oral sex is less well understood as a 
risk for HPV, the practice is increasingly linked to HPV infections. (D’Souza 2009).  Also 
important is that the facts above apply to heterosexual couples as well as homosexual 
couples, “straight” or same-sex partners.  Finally, the virus can be passed even when 
no symptoms are present or visible.  Several sources have indicated that transmission 
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is a common topic of concern among those with questions about HPV.  An 
observational study was conducted to collect and analyze survey data from participants 
who contacted an HPV hotline and email service.  The findings indicated that 
transmission was one of the concerns most often expressed about HPV (Herndon, 
2006). 
 
Signs and symptoms 
It is important to note that many people with genital HPV are asymptomatic – 
meaning they have no symptoms of the virus.  True too is that symptoms can often 
appear but be unrecognizable and thus a person may not realize they have the virus.  
As mentioned previously, there are different types of HPV with some causing genital 
warts and other causing cervical dysplasia.  Cervical cancer rarely has detectable 
symptoms, unless it is quite advanced (American Cancer Society, 2009).  Thus, 
information disseminated on the topic symptoms typically centers on genital warts only.  
For both women and men, symptoms of genital warts can appear anywhere below the 
waistline and above the upper thigh area (see Figure B and Figure C below from 
A.D.A.M. Images – one of the world's largest libraries of medical illustrations with nearly 
30,000 detailed and medically accurate images (A.D.A.M., 2010).  Contrary to what 
some individuals believe, the areas for symptoms include not just the penis and vagina, 
but also the anus, buttocks, scrotum, upper thighs, and perineum.  The bumps or warts 
can vary from one person to another and may appear as single or multiple painless 
bumps, be raised or flat, large or small, or shaped like a cauliflower.  They also may not 
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itch or be sensitive.  Finally, the symptoms may come and go with or without treatment 
of any kind and potentially recur if one’s immune response is weakened.   
Figure B: Female genital region   (From A.D.A.M. Images, 2010)  
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Risk and risk reduction 
Knowing the signs and symptoms mentioned above, one risk reduction approach 
regarding acquisition of genital HPV or any STI is to abstain from sexual activity while 
symptoms are present.  Using latex condoms can reduce the risk of transmission of 
genital HPV (Winer, 2006).  While they do not offer 100% protection, latex condoms do 
reduce skin-to-skin contact and therefore decrease the potential to pass or contract the 
virus.  Individuals can also lower the risk of contracting HPV by being in a monogamous 
relationship and/or limiting their number of sexual partners.  Additionally, vaccines can 
now prevent males and females from contracting HPV.  Two vaccines are currently 
available; Cervarix is available for females while Gardasil is available for both males 
and females (CDC, 2009).  Vaccines will be discussed in more detail below, but studies 
have shown that individuals and parents of minors are receptive to HPV vaccinations 
(Brewer, 2007). Finally, studies have shown that male circumcision has been found to 
reduce the likelihood of genital HPV in men (Castellsague, 2002) 
 
Testing 
Unfortunately, there is no test approved for clinical use to detect HPV infection in 
a man.  Although a Pap test is used to detect abnormal cell changes in the cervix and 
there are follow-up screening tests for HPV DNA, these are only used to help screen for 
cervical cancer in women (CDC, 2009).  Still, this should not deter a male from seeking 
consultation and diagnosis if they notice visible bumps or warts in the genital region. If a 
male or female has visible bumps or warts in the genital region, a doctor can provide a 
visual diagnosis; this can be done with the naked eye or a magnifying lens if needed.  
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Because there can be bumps in the genital region for reasons other than HPV infection 
(other STIs or skin conditions), it is recommended that a person with symptoms see 
their doctor for a diagnosis.  Regarding the Pap tests used to find abnormal cell 
changes in women, it is important for females and males to understand the need for 
screening, since the Pap test is very effective at finding cervical cancer early when it 
can be highly curable (American Cancer Society, 2009).  Screening frequency depends 
on several factors including age, previous screening history, results of the last Pap test, 
and the type of screening method being used (American Cancer Society, 2009) 
 
Treatment options 
HPV treatment for males and females is currently limited to genital warts.  While 
warts may resolve on their own, there are several treatments available with no single 
treatment considered a preferred method, as each decision should be on a case-by-
case basis.  Considerations for the type of treatment to use are based on the size, 
location, and number of warts or bumps.  Also important considerations are the cost 
implications for the individual, potential side effects, and considerations of past 
treatment success.  Per the CDC Treatment Guidelines, treatments include: imiquimod 
cream and podofilox cream/gel prescribed for patient application; podophyllin and 
trichloracetic acid (TCA) as available by a healthcare provider; cryotherapy, which is the 
freezing of warts/bumps with liquid nitrogen; electrocautery, which removes 
warts/bumps with an electric blade; laser therapy which uses an intense light to remove 
the warts/bumps; and finally surgical removal of the warts/bumps (CDC, 2009).  It is 
imperative that a male research his treatment options and then consult his healthcare 
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provider with any questions or concerns he may have prior to treatment.  Specific to 
females, the treatment options are the same, with special considerations for pregnancy, 
vaginal warts or cervical warts.   
 
Psychosocial issues 
Often the social or emotional impact of an STI diagnosis can be more difficult to 
deal with than any physical complications.  As I was quoted in an article for Sex, Etc., a 
magazine geared to younger adults sponsored by Rutgers, The State University of New 
Jersey, there are many misconceptions and preconceived notions about STIs and many 
people have inaccurate information (Sex, Etc., 2006).   It is common for someone, male 
or female, to feel upset after a diagnosis.  Just hearing that you have been diagnosed 
with an incurable virus can be daunting and cause even the most self-confident 
individual to be concerned about his or her future.  Yet, it’s important for one to realize a 
few solid facts about the virus in order to truly understand its impact on their current and 
future health and life as a whole.  First, there is no cure for any virus, even the common 
cold or flu, and that like many viruses, the human body responds to HPV by fighting the 
virus with its immune response.  Secondly, it is important to understand that genital 
HPV is common simply because sexual activity is common.  A key step is to understand 
that an individual is not a bad person for having HPV.  It is not uncommon for a person 
to feel upset about having the virus or to blame themselves.  Certainly, there are factors 
that increase one’s risk of contracting HPV such as multiple sex partners and lack of 
condom use, but the simple fact remains that any sexual activity brings with it some 
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level of risk.  Thirdly, one must understand the facts surrounding HPV including its 
different low risk and high risk types and also how both genders are affected. 
Returning to a sense of normalcy does not just happen overnight.  Upon a 
diagnosis or hearing that a partner has the virus is the time to obtain updated, accurate 
information if one is not already educated on the HPV virus.  Most people find that they 
are able to put HPV in perspective whether they, a partner, or both have the virus.  
Resources such as the CDC, American Social Health Association, American Cancer 
Society, and National Cancer Institute are just a few examples of reputable, non-
alarmist resources where individuals may receive helpful information on HPV and HPV-
associated cancers.  Succinctly put, HPV is a virus that tends to be a minor problem 
that can be resolved, if diagnosed early.  
 
Vaccines 
Perhaps one of the most important developments in vaccine research and 
certainly within the cancer arena in recent memory has been the successful creation of 
a vaccine for HPV.   Named Gardasil (pronounced “gard-Ah-sill”); it was approved by 
the United States Food and Drug Administration (FDA) in 2006 for the prevention of 
cervical cancer in girls and women between the ages 9 to 26 (Merck & Company, 
2006).  It was proven effective against the two high risk strains of HPV that can cause 
cervical cancer – types 16 and 18 (Merck & Company, 2006).  The vaccine is also 
virtually 100% effective in blocking persistent infections and diseases associated with 
the two low risk HPV types found with 90% of genital warts, HPV 6 and 11.  In clinical 
trials it was found to be most effective in women who had not yet been sexually active; 
hence, it is recommend to be administered to girls approximately 9 to 18 years of age 
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with the ideal age range being 11 to 12 since they likely have not yet had sexual activity 
(Merck & Company, 2006).  Women who are between the ages of 19 to 26 can also 
obtain the vaccine, but it is ideally given prior to a woman having sexual activity.  In 
October 2009, the Gardasil vaccine was approved for use in boys and men between the 
ages 9 to 26 for the prevention of genital warts.  As with females, this vaccine should 
ideally be administered to males prior to potential exposure to HPV from sexual contact 
(CDC, 2010).   
The guidelines and recommendations above have been advised by various 
parties including the FDA, CDC, ASHA, and the American Medical Association (AMA).  
However, these guidelines still vary in terms of implementation from state to state.  
There are many issues that affect the use of these vaccines, including but not limited to 
the acceptance of parents, cost implications, political climate, insurance coverage, and 
concerns over implications of sexual activity.  For example, parents can “opt out” of 
vaccination requirements in some states (ASHA, 2010).  Still, data show that parents in 
the United States have a positive attitude toward HPV vaccination (Brewer, 2007). 
Additionally, many pediatricians say they would administer the vaccine and support the 
use of its universal use (Abbigail, 2007).  Abbigail adds that specific strategies for 
vaccine delivery, availability of vaccines in various settings, guidance for addressing 
possible parental concerns, and specific educational initiatives were important to the 
successful implementation of the vaccines (Abbigail, 2007).  
 
Cancer 
Genital HPV can lead to various cancers as already noted.  By far the most 
common cancer caused by genital HPV in the United States is cervical cancer (CDC, 
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2009).  From the perspective of a male who is in a heterosexual relationship, being 
educated on HPV and aware of facts specific to females would be helpful – facts such 
as that Pap tests are a recommended screening tool to find cervical cancer early and 
that cervical cancer is more likely to occur in women who smoke, have HIV or AIDS, 
and who have poor nutrition (American Cancer Society, 2009).   
Still, other cancers can result from HPV, and whether male or female, it is 
important to note the chances of developing cancer from an HPV infection and speak to 
a healthcare provider about personal risk and recommendations on risk reduction.  
Specific to penile cancer and anal cancer, both are rare in the United States with about 
800 HPV-associated penile cancers and 3,000 HPV-associated anal cancers cases per 
year, yet it is important to know the symptoms of both (CDC, 2010).  For penile cancer, 
symptoms can include changes in color and thickness of the genital skin, redness, 
bumps, and sores.  Symptoms of anal cancer can include itching, bleeding, pain, and 
swelling in or near the anus.  All of these symptoms described for anal and penile 
cancer can occur for a variety of other reasons, thus consulting with one’s healthcare 
provider on such symptoms and on a regular basis is a good practice.  Basically, any 
male who notices changes to his genital or anal skin should consult with his provider. 
An important point for men who have sex with men (MSM) and/or for men who 
have or have had receptive anal sex, they may consider speaking with their healthcare 
provider about having a periodic Pap test in the anus.  Similar to a Pap test for a 
woman’s cervix, an anal Pap test involves a healthcare provider taking a swab of the 
anus in order to collect a sample of cells.  The sample is then examined under a 
microscope to determine if any cell changes are present.  While not common practice, 
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this method could be a considered screening option due to the potential risk of anal 
cancer.   
In terms of the various cancers, approximately 10,800 HPV-associated cervical 
cancers, 2,300 HPV-associated vulvar cancers, 600 HPV-associated vaginal cancers, 
800 HPV-associated penile cancers, 1,900 HPV-associated anal cancers in women and 
1,100 in men, and 1,700 HPV-associated head and neck cancers in women and 5,700 
in men occur in the United States each year per the CDC (CDC, 2009).  Head and neck 
cancers are not associated with genital HPV.  The three bar charts below detail the total 
number of HPV-associated cancers, anal cancers, and penile cancers from 1998 to 
2003 per 1,000 individuals and are provided courtesy of the CDC website.  As shown in 
Figure D, women are more commonly affected with more cases of cervical, vulvar, and 
vaginal cancer versus men with smaller numbers of HPV-associated cancer cases of 
the penis and anus.  Head and Neck cancers are included on the chart, but are not 
discussed here due to the discussion being on genital HPV. 
Figure D:  Yearly counts of HPV-associated cancers in the US, 1998–2003 
(CDC, 2009) 
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These figures from the CDC show how anal and penile cancers are broken down 
by race and ethnicity within the United States.   
Figure E: HPV-associated anal cancer rates by race and ethnicity, US, 
1998–2003 (CDC, 2009) 
 
Figure F: HPV-associated penile cancer rates by race and ethnicity, US, 
1998-2003 (CDC, 2009) 
 
 
   
22 
Genital HPV: How to Get Information to Men 
The challenges and concerns that HPV presents to men in the United States 
have been summarized and an overview of the relevant information has been provided. 
The challenge is, how does this type of information get into the hands of the individuals 
who need it?  What resources and opportunities are available to ensure that males of 
varying ages have access to the HPV information they need?  What challenges and 
limitations are there to funding, proper planning, assessment and implementation of 
such efforts?  Is there an interest and an audience, whether professional or public, that 
would be receptive to such information?  These important questions cannot be 
addressed in this setting alone; however, recommendations on which available 
communication venues can be used to conduct outreach to males can be introduced.  
Some good news is that since the initial planning phases of this master’s paper, several 
agencies have created male-specific educational materials geared to and about men.  
The American Social Health Association and CDC for example, created dedicated web 
pages tailored to the needs of men at: http://www.ashastd.org/hpv/hpv_learn_men.cfm 
and http://www.cdc.gov/std/hpv/stdfact-hpv-and-men.htm. This is an excellent first step 
in the right direction to having available HPV information that is of specific interest to 
males.   
Regarding comprehensive information on HPV, the creation of resources and 
implementation of targeted efforts are key considerations for an effective approach.  
Here, we will assume funding levels are limited and will not consider more expensive 
efforts such as multi-media approaches, extensive outreach projects, and the like.  We 
will however briefly review three communication venues that could be used to present 
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opportunities for increasing HPV education and awareness, and thus making an impact 
on the HPV situation.  These cost effective venues include: 
 Web-based initiatives 
 Schools 
 Healthcare providers 
 
Web-based initiatives 
 Communication options via the Internet have increased considerably as 
technological advances have occurred.  With the age of the internet and at-your-
fingertips information 24-hours-a-day, the appeal of offering information quickly and 
efficiently has benefited many facets of our country.  Education and outreach 
opportunities are no different.  There are many websites geared to public health, men’s 
health, sexually transmitted infections, reproductive health, behavioral sciences, 
adolescent health, and other topics that HPV could fall under.  Resources with the goal 
of providing health information to males, should consider offering basic information and 
reliable links to additional HPV resources.  The Internet provides options of downloading 
material, sharing dialogue, asking questions, networking with professionals, and posting 
materials; the opportunities are endless and also cost-effective.  With just a few clicks, 
detailed information can be posted and accessible to billions of Internet users across 
the world, and sensitive health questions can be answered in an anonymous, 
confidential manner.  Considering this opportunity, entities can continue or even 
increase the amount of HPV information and resources they provide to males.    
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 Of special mention is the increased use of social networking sites and 
advocacy/support group sites.  These venues provide cost-effective options for reaching 
specific populations.  It is possible to target varying male demographics by specific 
topics such as income, educational background, as well as by country or regions within 
the United States.  For example, an existing outreach program in North Carolina can 
advertise or market to males who reside in North Carolina and are of a specific age 
range by utilizing networks such as Facebook™ or MySpace™.    
 
Schools 
 Parents often find it difficult to discuss sex with their children and many may be 
lacking in knowledge of topics including HPV and condom efficacy.  This is important 
considering that sex is common in the teenage years (Guttmacher Institute, 2002).  
Even more importantly for adolescent males, studies suggest that young males have 
sexual activity earlier and a higher number of partners than females; both are factors 
associated with a higher risk of contracting an STI (Marcel, 2003).  Educational 
materials, resources, and referrals need to be made available to school-aged children 
as part of a comprehensive sexual education program.  Exactly at what age to 
implement such programs will vary depending on various factors including acceptance, 
political climate, parental concern, and funding.  The average age of first sexual 
intercourse for males and females is between 16 to 17 years of age (Kaiser, 2005).  
Thus, it is the recommendation of this author to begin comprehensive STI education, 
which includes basic HPV awareness, between the ages of 13 and 14.  This also 
coincides with the age recommendations for the cervical cancer vaccines. 
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Healthcare providers 
 Taking ownership with regard to providing both care and information on HPV 
should be a high priority for healthcare professionals who deal with this indication.  
Healthcare providers of men especially present an opportune venue for materials such 
as brochures, flyers, posters, and tools for HPV education.  Specialties and settings 
where males may frequent can include but not be limited to urologists, dermatologists, 
community clinics, proctologists, and health departments. The FDA should continue to 
play a key role in not only setting standards for testing and treatment, but also in 
providing resources and information to healthcare professionals who in turn can then 
disseminate information to their patients.  As Hamburg and Sharfstein point out in an 
article on the FDA, “Collaboration with sister public health agencies in the DHHS 
(Department of Health and Human Services), industry, consumer and patient 
organizations, and the public will lead to exciting opportunities for progress in public 
health.”   
 
Conclusion 
 With the high prevalence of HPV, estimated millions of new cases each year, and 
the identified health implications that affect women and men such as cervical or penile 
cancer, the time for males to get updated, tailored information is now.  As more 
research findings provide additional important HPV information and more 
communication venues are more easily accessible, opportunities exist for awareness at 
various age levels and to different male audiences.  Information on topics including HPV 
awareness, symptoms, testing, treatment, risk reduction, vaccines, and psychosocial 
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issues, is available and should be sought by and offered to sexually active males. 
Information dissemination via web-based efforts, schools and health care professionals 
can play a key role in the successful implementation of HPV awareness campaigns and 
prevention efforts.  Vaccination programs are of special importance considering the 
proven efficacy of the current HPV vaccines and their availability to both females and 
males.  Coupled with risk reduction measures, it is clear the call to action for the male 
population in the United States is here.  Ultimately, any perceived barriers, limitations 
and challenges should be viewed as potential opportunities for education, awareness 
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